Bristol-Myers Squibb Company Profile: Stock Performance ... Bristol-Myers Squibb General Information Description. Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Events and Presentations - Bristol Myers Squibb Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the company’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These wide-moat companies are rare value deals in ... Bristol-Myers Squibb (BMY) discovers, develops and markets drugs for cardiovascular and infectious diseases, cancer and immune disorders. The firm's primary focus is immuno-oncology, where it is a leader in drug development. With strategic partnerships and acquisitions, Bristol-Myers has built a strong portfolio of drugs and a robust pipeline.
GRYT Health and Bristol Myers Squibb ... - Morningstar, Inc. May 12, 2020 ETFs with Bristol-Myers Squibb Co (BMY) Exposure | ETF ... The following ETFs maintain exposure to Bristol-Myers Squibb Co (BMY). ETF holdings data are updated once a day, and are subject to change. To see a complete breakdown of any of the ETFs included in the table below, including sector, market cap, and country allocations, click on the ticker symbol.
BMY debt, bond, rates, quotes, yields - Morningstar Bristol Myers Squibb 3.25% | Maturity:2027 Print Report Data Question Quote We value your feedback. Let us know what you think. Content Partners Site Directory Site Map Our Products. Corrections Help Advertising Opportunities Licensing BMY Stock Analyst Coverage - Bristol Myers Squibb Bristol Myers Squibb is followed by the analysts listed above. Their research and estimates are included in consensus estimates with Firstcall Research or FactSet.Please note that any opinions, estimates or forecasts regarding Bristol Myers Squibb's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Bristol Myers Squibb or its management.
Bristol-Myers Squibb Company 百时美施贵宝公司 ; 百时美施贵宝 ; 施贵宝公司 ; 阿斯利康制药有限公司分装 更多 收起 网络短语. 相关文章. 双语例句 原声例句 权威例句. That is the ultimate goal for the
纽约股市方面，高盛公司把百时美施贵宝公司（Bristol-Myers Squibb）的评级从"中性"调高到"买入"后，这家制药商的股价上涨5.4%。 Bristol-Myers Squibb Co. jumped 5.4 percent in New York after Goldman Sachs Group Inc. raised its rating on the drugmaker to "buy" from "neutral. Para ser incluida en la estrategia Wide Moat Focus, una compañía debe tener una ventaja competitiva (o Economic Moat) amplia (lo que significa que pensamos que disfruta de unas ventajas que la defenderán de los competidores durante al menos 20 años), y sus acciones deben cotizar con un descuento respecto a nuestro fair value (o precio objetivo). Bristol-Myers Squibb stellt sich aggressiv auf, um durch Wachstum die Patentklippe zu umschiffen. Dank der Vorliebe für Kooperationen und Übernahmen hat das Unternehmen ein solides Arzneimittelportfolio und eine stabile Pipeline aufgebaut. Wir sind der Ansicht, dass dadurch Patentlücken in den nächsten zehn Jahren - insbesondre im Bereich 雪球为您提供undefined(undefined)股票实时行情,资金流向,新闻资讯,研究报告,社区互动,交易信息,个股点评,公告,财务指标分析等与undefined(undefined)股票相关的信息与服务. This is the historical insider ownership of Bristol-Myers Squibb Company. It is usually better to buy companies with large insider ownership. The company insiders' interest are more aligned with external shareholders in this case. Le cours de l'action BRISTOL-MYERSSQU BMY sur Boursorama : historique de la cotation sur NYSE, graphique, actualités, consensus des analystes et informations boursières